What Happened to the Migraine Drug

You cannot compete with Zecuity for the ridiculous priced unneeded migraine treatment market!
Bring it on boys!

 

The puffer has a Approval delay till April 2016 at earliest. No National meeting in Feb. Possible launch in May,June, July time frame.

 

Possible approval in Feb.

 

Are migraine specialists truly interested and eager for the approval of this product??

 

As much as Neuros/Psychs are interested in Rxing Nuedexta for its true indicate

 

So what are they writing it for? You keep talking here about off label.

 

Would you be interested in using your own breath to blow a powder up each nostril, carry a big device around with you everywhere you do and pay 5x more for this product for a POSSIBLE 15 min quicker onset of action for a migraine? I would say maybe 2% of the market would say yes. IF you use basic logic the answer to your question the answer is no.

In addition the newer class of migraines coming out prevent migraines decreasing the demand for this class of medication. Mark my words this will be a huge bust.

 

The only use is to fill it with Coke to blow it up your nose better. That should drive sales.
As far as migraine you would have to be a moron to prescribe or use it.

 

Well let's hope the consultants didn't fill senior leadership with some delusion as to what the post launch sales will look like.

 

Then don't work here asshole concern troll...wait they thumbed you off long ago.

 

lol WTF is "thumbed you off" Is that even an actual phrase that has any meaning or did you just make that up now?

I am hoping my posts will scare others off so they don't interview and I can get a spot here remember?!? LOL!!

 

Sweet. What's your dress size?

 

7.3 inches of limp dick. Now get on your knees ho.

 

Migraine Approval in Feb 2016
Expansion hiring will be when new migraine drug is approved and
not a minute before.

 

Thanks Denise.

 

Like I said above the newer migraine products will not only treat the pain but PREVENT migraines. This is 1 of 3 products in this class set to launch by big pharma in the next 2 years. Still think the nose blower will be a success? LOL!


- Teva to Receive Worldwide Development and Commercial Rights to Novel CGRP Antagonists
- Heptares to Receive $10 Million Upfront with up to $400 Million in Potential Milestone Payments

JERUSALEM & LONDON--(BUSINESS WIRE)--

Teva Pharmaceutical Industries Ltd. (NYSE and TASE:TEVA) and Heptares Therapeutics (“Heptares”), a wholly owned subsidiary of Sosei Group Corporation (“Sosei”; TSE Mothers Index: 4565) announce that they have entered into a licensing and drug-discovery agreement under which Teva will receive exclusive global rights to develop, manufacture and commercialize novel, small-molecule calcitonin gene-related peptide (CGRP) antagonists discovered by Heptares for the treatment of migraine.

Under the terms of the agreement, Heptares will receive an upfront payment of $10 million, research funding, and is eligible to receive additional research, development and commercialization milestone payments of up to $400 million. In addition, Heptares will be eligible to receive royalties on net sales of products resulting from the alliance.

“We are delighted to begin this partnership with Heptares, which through its industry-leading, structure-based design approach has generated novel CGRP antagonists with significant promise for treating migraine,” said Michael Hayden, MD, PhD, President of Global R&D and Chief Scientific Officer at Teva. “CGRP antagonism represents an exciting opportunity to treat migraine. We believe small-molecule CGRP antagonists offer further opportunities that are highly complementary to our promising candidate, TEV-48125, an anti-CGRP antibody.”

“This agreement is an exciting development for our CGRP antagonist program,” added Malcolm Weir, Chief Executive Officer of Heptares. “Teva brings world-leading clinical and commercial expertise in migraine to advance this program based on differentiated small-molecule CGRP antagonists discovered using our novel structure-based drug design technologies. The commitment Teva is making allows us to expand this promising program.”


About CGRP Antagonists for Migraine

Calcitonin gene-related peptide (CGRP) is released during migraine attacks and can trigger migraine in patients. CGRP is found in small to medium-sized neurons in the trigeminal ganglion and mediates its activity through G protein-coupled receptors located throughout the body. Elevated levels of CGRP are found in migraineurs during an attack and blocking CGRP activity is a validated mechanism of action for relieving pain, and also for preventing migraine.

 

Thanks Denise for what?

 

Onzetra will be here in April 2016

 

Not true
http://www.wsj.com/articles/allergan-buys-rights-to-mercks-migraine-drugs-1436268370

Bayer bought the consumer products from Merck
Just setting the record straight